258 results on '"Burlina, Alessandro P"'
Search Results
2. Health-related quality of life in a european sample of adults with early-treated classical PKU
3. Correction: Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
4. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry
5. Newborn screening for Pompe disease in Italy: Long-term results and future challenges
6. Effect of enzyme substitution therapy on brain magnetic resonance imaging and cognition in adults with phenylketonuria: A case series of three patients.
7. Newborn Screening for Acid Sphingomyelinase Deficiency: Prevalence and Genotypic Findings in Italy.
8. Opinion, knowledge, and clinical experience with functional neurological disorders among Italian neurologists: results from an online survey
9. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
10. Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
11. Stroke management during the coronavirus disease 2019 (COVID-19) pandemic: experience from three regions of the north east of Italy (Veneto, Friuli-Venezia-Giulia, Trentino-Alto-Adige)
12. Detection of 3-O-methyldopa in dried blood spots for neonatal diagnosis of aromatic L-amino-acid decarboxylase deficiency: The northeastern Italian experience
13. Fabry Disease
14. Neuroimaging of Inherited Metabolic Diseases of Adulthood
15. Inflammation and impaired autophagy in Gaucher disease type 1 infants diagnosed by newborn screening
16. Neonatal screening for Fabry disease and long-term follow-up: The role of plasma globotriaosylsphingosine (LysoGb3) assay
17. Acute revascularization treatments for ischemic stroke in the Stroke Units of Triveneto, northeast Italy: time to treatment and functional outcomes
18. Stroke in patients with Fabry disease: A Fabry Registry analysis of natural history data from patients stratified by disease phenotype
19. Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy
20. Eye Disorders
21. Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy.
22. Non‐Hodgkin lymphoma in a kidney transplanted patient with methylmalonic acidemia: Metabolic susceptibility and the role of immunosuppression.
23. Intravenous thrombolysis for ischemic stroke in the Veneto region: the gap between eligibility and reality
24. Newborn Screening for Fabry Disease: Current Status of Knowledge
25. Chapter 10 - Lysosomal storage diseases
26. Inborn Errors of Metabolism
27. Long‐term follow‐up of a patient with neonatal form of Gaucher disease
28. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy
29. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage
30. Eye Disorders
31. N-Acetylaspartylglutamate (NAAG) in Pelizaeusmerzbacher Disease
32. Hypoacetylaspartia: Clinical and Biochemical Follow-Up of a Patient
33. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS
34. Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases
35. Bone disease in early detected Gaucher Type I disease: A case report
36. Eye Disorders
37. Whole-blood alpha- D-galactosidase A activity for the identification of Fabry's patients
38. Mutational Screening of NOTCH3 Gene Reveals Two Novel Mutations: Complexity of CADASIL Diagnosis
39. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
40. Apparent diffusion coefficient restriction in the white matter: going beyond acute brain territorial ischemia
41. Diagnosis and management of glutaric aciduria type I – revised recommendations
42. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy
43. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria
44. Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
45. Bone disease in early detected Gaucher Type I disease: A case report.
46. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage
47. MR Spectroscopy: A Powerful Tool for Investigating Brain Function and Neurological Diseases
48. Fabry disease and COVID-19: International expert recommendations for management based on real-world experience
49. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
50. The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.